DK0733214T3 - Tætte mikrosfærekomponenter afledt af mammalt hjernevæv samt antistoffer rettet mod disse - Google Patents
Tætte mikrosfærekomponenter afledt af mammalt hjernevæv samt antistoffer rettet mod disseInfo
- Publication number
- DK0733214T3 DK0733214T3 DK95903728T DK95903728T DK0733214T3 DK 0733214 T3 DK0733214 T3 DK 0733214T3 DK 95903728 T DK95903728 T DK 95903728T DK 95903728 T DK95903728 T DK 95903728T DK 0733214 T3 DK0733214 T3 DK 0733214T3
- Authority
- DK
- Denmark
- Prior art keywords
- dms
- well
- antibodies
- directed against
- cerebral amyloid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/839—Nerves; brain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/168,250 US5525339A (en) | 1986-08-27 | 1993-12-17 | Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto |
PCT/CA1994/000689 WO1995016917A1 (en) | 1993-12-17 | 1994-12-19 | Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0733214T3 true DK0733214T3 (da) | 1999-03-15 |
Family
ID=22610731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK95903728T DK0733214T3 (da) | 1993-12-17 | 1994-12-19 | Tætte mikrosfærekomponenter afledt af mammalt hjernevæv samt antistoffer rettet mod disse |
Country Status (10)
Country | Link |
---|---|
US (4) | US5525339A (de) |
EP (1) | EP0733214B1 (de) |
JP (1) | JPH09507748A (de) |
AT (1) | ATE165918T1 (de) |
AU (1) | AU702153B2 (de) |
CA (1) | CA2175451C (de) |
DE (1) | DE69410116T2 (de) |
DK (1) | DK0733214T3 (de) |
ES (1) | ES2118545T3 (de) |
WO (1) | WO1995016917A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525339A (en) * | 1986-08-27 | 1996-06-11 | Dms Pharmaceutical Inc. | Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto |
US5231170A (en) * | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
US6413940B1 (en) * | 1997-02-07 | 2002-07-02 | Nymox Corporation | Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS |
US7514407B2 (en) * | 2002-03-04 | 2009-04-07 | Nymox Corporation | Spheron component peptides and pharmaceutical compositions |
US20040002460A1 (en) * | 2002-03-04 | 2004-01-01 | Paul Averback | Spheron components useful in determining compounds capable of treating symptoms of Alzheimer's disease, and treatments and animal models produced therefrom |
BR0315157A (pt) * | 2002-10-09 | 2005-08-09 | Rinat Neuroscience Corp | Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
KR101068289B1 (ko) * | 2004-07-30 | 2011-09-28 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법 |
PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
ES2453941T5 (es) | 2005-11-30 | 2017-05-31 | Abbvie Inc. | Anticuerpos monoclonales contra la proteína beta amiloide y usos de los mismos |
BRPI0619249A2 (pt) | 2005-11-30 | 2011-09-20 | Abbott Lab | anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos |
KR101591206B1 (ko) | 2005-12-12 | 2016-02-04 | 에이씨 이뮨 에스.에이. | 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체 |
EP2046833B9 (de) | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanisierter antikörper gegen amyloid beta |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
EP2558494B1 (de) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta-bindende proteine |
NZ606357A (en) | 2010-07-30 | 2015-05-29 | Genentech Inc | Safe and functional humanized anti beta-amyloid antibody |
EP3533803B1 (de) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antikörper |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525339A (en) * | 1986-08-27 | 1996-06-11 | Dms Pharmaceutical Inc. | Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto |
US6727278B1 (en) * | 1986-08-27 | 2004-04-27 | Dms Pharmaceutical Inc. | Pharmaceutically active agents that impede amyloid formation in vivo |
US5231170A (en) * | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
US4919915A (en) * | 1987-03-03 | 1990-04-24 | Paul Averback | Method for detecting the ability to prevent red-to-green congophilic birefringence |
US4816416A (en) * | 1986-08-27 | 1989-03-28 | Paul Averback | Microspheric bodies for use in screening therapies for Azheimer's disease and related conditions |
US5262332A (en) * | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
US5234814A (en) * | 1989-06-01 | 1993-08-10 | Du Pont Merck Pharmaceutical Company | Diagnostic assay for alzheimer's disease |
US5100645A (en) * | 1990-10-19 | 1992-03-31 | Royal Institution For The Advancement Of Learning (Mcgill Univ.) | Method of diagnosis of amyloidosis |
US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US6413940B1 (en) * | 1997-02-07 | 2002-07-02 | Nymox Corporation | Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS |
US6130221A (en) * | 1997-03-05 | 2000-10-10 | Nymox Corporation | Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions |
US6913745B1 (en) * | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
-
1993
- 1993-12-17 US US08/168,250 patent/US5525339A/en not_active Expired - Fee Related
-
1994
- 1994-12-19 JP JP7516431A patent/JPH09507748A/ja active Pending
- 1994-12-19 CA CA002175451A patent/CA2175451C/en not_active Expired - Fee Related
- 1994-12-19 AU AU12695/95A patent/AU702153B2/en not_active Ceased
- 1994-12-19 EP EP95903728A patent/EP0733214B1/de not_active Expired - Lifetime
- 1994-12-19 WO PCT/CA1994/000689 patent/WO1995016917A1/en active IP Right Grant
- 1994-12-19 DE DE69410116T patent/DE69410116T2/de not_active Expired - Fee Related
- 1994-12-19 ES ES95903728T patent/ES2118545T3/es not_active Expired - Lifetime
- 1994-12-19 AT AT95903728T patent/ATE165918T1/de not_active IP Right Cessation
- 1994-12-19 DK DK95903728T patent/DK0733214T3/da active
-
1996
- 1996-06-10 US US08/660,886 patent/US6309892B1/en not_active Expired - Fee Related
-
2001
- 2001-10-29 US US09/984,304 patent/US20020028473A1/en not_active Abandoned
-
2004
- 2004-12-29 US US11/024,223 patent/US20050191711A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU702153B2 (en) | 1999-02-18 |
EP0733214A1 (de) | 1996-09-25 |
AU1269595A (en) | 1995-07-03 |
DE69410116T2 (de) | 1998-12-17 |
ATE165918T1 (de) | 1998-05-15 |
US5525339A (en) | 1996-06-11 |
EP0733214B1 (de) | 1998-05-06 |
US20020028473A1 (en) | 2002-03-07 |
ES2118545T3 (es) | 1998-09-16 |
US20050191711A1 (en) | 2005-09-01 |
JPH09507748A (ja) | 1997-08-12 |
CA2175451C (en) | 2000-10-31 |
WO1995016917A1 (en) | 1995-06-22 |
DE69410116D1 (de) | 1998-06-10 |
US6309892B1 (en) | 2001-10-30 |
CA2175451A1 (en) | 1995-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0733214T3 (da) | Tætte mikrosfærekomponenter afledt af mammalt hjernevæv samt antistoffer rettet mod disse | |
US5443960B1 (en) | Method for the diagnosis of blood coagulation disorders | |
HUP9902068A3 (en) | Methods and compositions for the diagnosis and treatment of cancer | |
DE69833971D1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
CA2123211A1 (en) | A method for assaying and treating alzheimer's disease | |
EP0808324A4 (de) | Zusammensetzungen und verfahren zur behandlung und diagnose kardiovaskulärer erkrankungen | |
AU8494291A (en) | Methods of treating, diagnosing and monitoring therapies from levels of human oubain-like factor and antibody thereof | |
SE9404196D0 (sv) | New antithrombotic formulation | |
ES2179843T3 (es) | Metodo para la abertura selectiva de capilares de tejido cerebral anormal. | |
DK0723444T3 (da) | Levobupivacain, som er egnet til behandling af kronisk smerte | |
WO1995024650A3 (en) | Methods of diagnosing and treating preeclampsia | |
EP0251585A3 (de) | Behandlung von Eisen enthaltenden unterirdischen Formationen | |
TR199900951T2 (xx) | G���s kanserinin engellenmesi i�in y�ntemler. | |
KR950700726A (ko) | 치료 또는 진단용 조성물, 그 제조방법 및 용도(composition for therapeutic or diagnostic use, process for its preparation and its use) | |
WO1999048489A3 (en) | Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders | |
AU5153398A (en) | Diagnostic method for the detection of alzheimer's disease in living patients | |
BR9508435A (pt) | Quelentes macrocíclicos seus quelatos e usos dos mesmos no campo diagnóstico | |
KR890700353A (ko) | 면역독소의 면역억제 기저 사람치료법 | |
Baron et al. | Immunomodulatory effect of extracorporeal photopheresis after successful treatment of resistant renal allograft rejection | |
WO2002062205A3 (en) | Methods for diagnosing and treating heart disease | |
WO2001042205A3 (en) | Treatment of inflammatory bowel disease with vitamin d compounds | |
WO2003028536A3 (en) | Methods for diagnosing and treating heart disease | |
IL114548A0 (en) | Complex compounds for diagnosis of vascular diseases | |
AU4841296A (en) | Diagnosis of and compositions and methods for the treatment of disease | |
WO2002018633A3 (en) | Determination of the ability of patients to respond to tumour treatment |